Sangamo BioSciences Stock News

Sangamo Therapeutics Inc. (NASDAQ:SGMO) price on Thursday, November 18, fall -2.10% below its previous days close as a downside momentum from buyers pushed the stocks value to $9.32. A look at the stocks price movement, the close in the last trading session was $9.52, moving within a range at $9.265 and $9.67. The beta value Honey At Sangamo Therapeutics Inc. (SGMO) Is Worth Your Money Read More »

Wall Street brokerages forecast that Sangamo Therapeutics, Inc. (NASDAQ:SGMO) will post sales of $29.15 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Sangamo Therapeutics earnings, with the lowest sales estimate coming in at $28.00 million and the highest estimate coming in at $32.00 million. Sangamo Therapeutics posted sales []

The mean of analysts' price targets for Sangamo (SGMO) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

Sangamo Therapeutics Inc (NASDAQ: SGMO) announced preliminary results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a gene therapy candidate for Fabry disease.  A

Sangamo Therapeutics' (SGMO) CEO Sandy Macrae on Q3 2021 Results - Earnings Call Transcript

Sangamo (SGMO) delivered earnings and revenue surprises of 2.94% and 5.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial

Sangamo has transitioned to what they called Wave 2 a couple years ago. Biogen and Novartis have partnered with Sangamo to pursue gene regulation. These partnerships are actively being grown with two

Sangamo Therapeutics: Finding An Opportunity To Reload

Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the 2021 Wedbush PacGro

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2021 Results - Earnings Call Transcript

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2021 financial results. “This i

Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest S

CRISPR can be utilized ubiquitously as a search and replace tool allowing scientists to identify DNA sequences. The potential uses of CRISPR are numerous across a large variety of fields including agr